Pharmacological augmentation strategies in clozapine-resistant schizophrenia: Overcoming the resistance;Estrategias farmacológicas de potenciación en esquizofrenia refractaria a clozapina: Más alla de la resistencia

Psiquiatria Biologica

Volumn 17, Issue 3, 2010, Pages 96-101

  Ruiz Doblado, Sergio ^a   Baena Baldomero, Antonio ^a   Espárrago Llorca, Guadalupe ^a  

^a HOSPITAL DE LA MERCED   (Spain)

Author keywords

Amisulpride; Augmentation; Clozapine; Lamotrigine; Resistant schizophrenia; Risperidone; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; LAMOTRIGINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID; RISPERIDONE; VALPROIC ACID;

AGRANULOCYTOSIS; CLINICAL TRIAL; DRUG DOSE INCREASE; HUMAN; REFRACTORY PERIOD; REVIEW; SCHIZOPHRENIA; SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77957369070     PISSN: 11345934     EISSN: 15788962     Source Type: Journal    
DOI: 10.1016/j.psiq.2010.07.002     Document Type: Short Survey

References (61)

1. J.M. Palacios-Santibaez, and G. Mengod Losarcos Selectividad regional de los antipsicticos atpicos C. Garca-Ribera, Nuevos antipsicticos atpicos 1996 Masson Barcelona 25 41
2. S. Stahl Clozapina S. Stahl, Psicofarmacologa esencial 2002 Ariel Neurociencia Barcelona 480 482
3. J. Gerlach, and E. Casey Drug treatment of schizophrenia: Myths and realities Curr Opin Psychiatry 7 1994 65 70
4. C. Alamo, E. Cuenca, and F. Lpez Antipsicticos atpicos: perfil receptorial C. Garca-Ribera, Nuevos antipsicticos atpicos 1996 Masson Barcelona 1 24
5. H.I. Kaplan, and B.J. Sadock Clozapina H.I. Kaplan, B.J. Sadock, Manual de Farmacoterapia en Psiquiatra 1993 Waverly Hispnica Buenos Aires 99 103
6. J. Gerlach, and C. Garca-Ribera Antipsicticos atpicos: de los modelos animales a los efectos clnicos C. Garca-Ribera, Nuevos antipsicticos atpicos 1996 Masson Barcelona 43 65
7. RM Dardennes, NN Al Anbar, and F Rouillon Succesful augmentation of clozapine-resistant treatment of schizophrenia with clonidine Prog Neuropsychopharmacol Biol Psychiatry 34 2010 724 725
8. C. Barnas, H. Zwierzina, and M. Hummer Granulocite-macrophage colony stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case-report J Clin Psychiatry 53 1992 245 247
9. E. Alvarez Experiencia en Espaa con los antipsicticos atpicos C. Garca-Ribera, Nuevos antipsicticos atpicos 1996 Masson Barcelona 83 101
10. A.Z. Safferman, J.A. Lieberman, J.M. Kane, S.R. Saymaski, and B.J. Kinon Clozapina en la esquizofrenia refractaria a tratamiento C.L. Shriqui, H.A. Nasrallah, Aspectos actuales en el tratamiento de la esquizofrenia 1995 Edimsa Madrid 367 413
11. J. Idanpaan-Heikkila, E. Alhava, and M. Olkinuera Agranulocytosis during treatment with clozapine Eur J Clin Pharmacol 11 1977 193 198
12. J.A. Lieberman, C. Johns, and J.M. Kane Clozapine induced agranulocytosis: non-cross reactivity with other psychotropic drugs J Clin Psychiatry 49 1988 271 277
13. J.A. Lieberman, J. Yunis, and E. Egea HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia Arch Gen Psychiatry 47 1990 945 948
14. J. Tiihonen, J. Lonnqvist, K. Wahlbeck, T. Klaukka, L. Niskanen, and A. Tanskanen 11 year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet 374 2009 620 627
15. H.Y. Meltzer Treatment of neuroleptic-nonresponsive schizophrenic patient Schizophr Bull 18 1992 515 542
16. H.Y. Meltzer, and G. Okayli Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia. Impact on risk-benefits assessment Am J Psychiatry 152 1995 183 190
17. W.T. Carpenter, R.R. Conley, R.W. Buchanan, A. Breier, and C. Tamminga Patient response and resource management: Another view of clozapine treatment of schizophrenia Am J Psychiatry 152 1995 827 832
18. J. Kane, G. Honigfeld, and J. Singer Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benzotropine Arch Gen Psychiatry 45 1988 789 796
19. R.L. Borison, B.I. Diamond, and D. Sinha Clozapine withdrawal rebound psychosis Psychopharmacol Bull 24 1988 260 263
20. R.R. Conley, S.C. Schulz, and R.W. Baker Clozapine efficacy in schizophrenic nonresponders Psychopharmacol Bull 24 1988 269 274
21. D. Pickard, R.R. Owen, and R.E. Litman Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine Arch Gen Psychiatry 49 1992 345 353
22. L.H. Lindstrom The effect of long term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years Acta Psychiatr Scand 77 1988 524 529
23. H.Y. Meltzer, B. Bastani, and K. Youngkwon A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report Psychopharmacology (Berl) 99 1989 S68 S72
24. J.A. Mattes Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years J Clin Psychiatry 50 1989 389 391
25. R.R. Owen, B.J. Beake, and D. Marby Response to clozapine in chronic psychotic patients Psychopharmacol Bull 25 1989 253 256
26. V.P. Kontaxakis, P.P. Ferentinos, B.J. Havaki-Kontaxaki, K.G. Paplos, D.K. Roukas, and G.N. Christodoulou Case studies of adjunctive agents in clozapine-resistant schizophrenic patients Clin Neuropharmacol 28 2005 50 53
27. V.P. Kontaxakis, P.P. Ferentinos, B.J. Havaki-Kontaxaki, and D.K. Roukas Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review Eur Psychiatry 20 2005 409 415
28. G. Remington, A. Saha, S.A. Chong, and C. Shammi Augmentation strategies in clozapine-resistant schizophrenia CNS Drugs 19 2005 843 872
29. F. Mouaffac, C. Tranullis, R. Gourevitch, M.F. Poirier, S. Douki, and J.P. Olie Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia Clin Neuropharmacol 29 2006 28 33
30. F. Centorrino, R.J. Baldessarini, J.C. Kando, F.R. Frankeburg, S.A. Volpicelli, and J.G. Flood Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients J Clin Psychopharmacol 14 1994 119 125
31. S. Ulrich, B. Baumann, R. Wolf, D. Lehmann, B. Peters, and B. Bogerts Therapeutic drug monitoring of clozapine and relapse a retrospective study of routine clinical data Int J Clin Pharmacol Ther 41 2003 3 13
32. Y.Q. Xiang, Z.J. Zhang, Y.Z. Weng, Y.M. Zhai, W.B. Li, and Z.J. Cai Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia Schizophr Res 83 2006 201 210
33. C. Greenwood-Smith, D.I. Lubman, and D.J. Castle Serum clozapine levels: a review of their clinical utility J Psychopharmacol 17 2003 234 238
34. A. Cipriani, M. Boso, and C. Barbui Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia Cochrane Database Syst Rev 8 2009 CD006324
35. D.C. Goff, O. Freudenreich, and A.E. Evins Augmentation strategies in the treatment of schizophrenia CNS Spectr 6 2001 907 911
36. A.E. Anil, I.T. Turgut, M. Rezaki, and A. Gogus A review on augmentation of clozapine treatment Turk Psikiyatri Derg 13 2002 65 77
37. M. Zink, S. Englisch, and A. Meyer-Lindenberg Polypharmacy in schizophrenia Curr Opin Psychiatry 23 2010 103 111
38. J. Munro, P. Matthiasson, S. Osborne, M. Travis, S. Purcell, and A.M. Cobb Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine Acta Psychiatr Scand 110 2004 292 298
39. A. Kreinin, D. Novitski, and A. Weizman Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study Int Clin Psychopharmacol 21 2006 99 103
40. J. Wang, I.M. Omori, M. Fenton, and B. Soares Sulpiride augmentation for schizophrenia Cochrane Database Syst Rev 1 2010 CD008125
41. Y. Genc, E. Taner, and S. Candansayar Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study Adv Ther 24 2007 1 13
42. L. Pani, J.M. Villagran, V.P. Kontaxakis, and K. Alptekin Practical Issues with amisulpride in the management of patients with schizophrenia Clin Drug Investig 28 2008 465 477
43. R.C. Josiassen, A. Joseph, E. Kohegyi, S. Stokes, M. Dadvand, and W.W. Paing Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial Am J Psychiatry 162 2005 130 136
44. V.P. Kontaxakis, P.P. Ferentinos, B.J. Havaki-Kontaxaki, K.G. Paplos, D.A. Pappa, and G.N. Christodoulou Risperidone augmentation of clozapine: a critical review Eur Arch Psychiatry Clin Neurosci 256 2006 350 355
45. M. Zink, E. Mase, and H. Dressing Ziprasidone-augmentation of clozapine Psychiatr Prax 31 2004 259 261
46. K. Karunakaran, T.E. Tungaraza, and G.C. Harborne Is clozapine- aripiprazol combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 21 2007 453 456
47. S.C. Stoner, M.M. Dahmen, A. Berges, and W.M. Petry Augmentation of aripiprazole with low-dose clozapine Pharmacotherapy 27 2007 1599 1602
48. T. Snchez-Araa Moreno, J.M. Gonzlez-Moreno, T. Rueda-Villar, and S. Ruiz-Doblado Potenciacin de clozapina con aripiprazol en esquizofrenia resistente: informe de casos Psiq Biol 14 2007 77 80
49. H.J. Williams, C.R. Zamzow, H. Robertson, and S.M. Dursun Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity Prog Neuropsychopharmacol Biol Psychiatry 30 2006 239 243
50. S.M. Dursun, D. McIntosh, and H. Milliken Clozapine plus lamotrigine in treatment-resistant schizophrenia Arch Gen Psychiatry 56 1999 950
51. S.M. Dursun, and J.F.W. Deakin Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment resistant schizophrenia: a naturalistic case-series outcome study J Psychopharmacol 15 2001 297 301
52. J. Tiihonen, T. Hallikainnn, O.P. Ryynanen, E. Repo-Tiihonen, I. Kotilinen, and M. Eronen Lamotrigine in treatment-resistant schizophrenia: a randomized, placebo-controlled, cross-over trial Biol Psychiatry 54 2003 1241 1248
53. I. Kremer, A. Vass, I. Gorelik, G. Bar, M. Blanaru, and D.C. Javitt Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia Biol Psychiatry 56 2004 441 446
54. R. Zoccalli, M.R. Muscatello, A. Bruno, R. Cambria, U. Mic, and E. Spina The effect of lamotrigine augmentation in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study Schizophr Res 93 2007 109 116
55. D.C. Goff, R. Keefe, L. Citrome, K. Davy, J.H. Krystal, and C. Large Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials J Clin Psychopharmacol 27 2007 582 589
56. J. Tiihonen, K. Wahlbeck, and V. Kiviniemi The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis Schizophr Res 109 2009 10 14
57. A.J. Ramsey NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia Prog Brain Res 179 2009 51 58
58. M Vrajova, F Stastny, J Horacek, J Lochman, O Sery, and S Pekova Expression of the Hippocampal NMDA Receptor GluN1 Subunit and its splicing isoforms in schizophrenia: post-mortem study Neurochem Res 35 2010 994 1002
59. G.J. Marek, B. Behl, A.Y. Bespalov, G. Gross, Y. Lee, and H. Schoemaker Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77 2010 317 326
60. GE Tsai, and PY Lin Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia: A critical review and meta-analysis Curr Pharm Des 16 2009 522 537
61. C. Chaves, C.R. Marqu, C. Trzesniak, J.P. Machado de Sousa, A.W. Zuardi, and J.A. Crippa Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: An update Braz J Med Biol Res 42 2009 1002 1014